Cargando…
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
The diagnosis of Parkinsonian disorders is currently based on clinical criteria, which have limited sensitivity until most dopaminergic neurons are lost. Here we show that cerebrospinal fluid levels of DOPA decarboxylase (DDC) (also known as aromatic l-amino acid decarboxylase) can accurately identi...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570139/ https://www.ncbi.nlm.nih.gov/pubmed/37723208 http://dx.doi.org/10.1038/s43587-023-00478-y |